Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (1294)	7/2/2000 11:13:53 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Torben, Insomnia - Know of anyone else? SEPR has a very significant insomnia entry - an isomer of Zopiclone. Zopiclone (Imovane) is the biggest-selling European drug, but was never the subject of a US IND. SEPR has licensed the RPR European data, and pivotal US trials of (+)-Zopiclone should start later this year. The SEPR ICE apparently claims reduced anticholinergic side effects (in particular dry mouth). It also seems to have a wider therapeutic window that its parent. SEPR thinks that they may be able to market it in two doses - one for people that just have trouble falling asleep, and a higher dose for people that wake up in the middle of the night. Existing drugs like Sonata work for only a short time (4 hours), and you need to take another dose if you wake up during the night. On the other hand, Sonata doesn't leave you groggy in the morning, and it is unclear to me whether the higher dose of the SEPR drug might produce morning drowsiness. Here is the latest SEPR release on this candidate: corporate-ir.net Peter